Latest Commercialization News

Activeport Group launches Asia’s inaugural software-orchestrated Network-to-Network Interconnect Exchange in Singapore, integrating Megaport’s global data centre connectivity to transform cross-border telecom services.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

Nanoveu Limited’s transformative half-year report highlights its EMASS acquisition, executive hires, and technology advances amid a $3 million loss and new US OTCQB listing.

RLF AgTech Ltd has reported a remarkable financial turnaround in FY25, with revenues more than doubling and losses narrowing significantly, setting the stage for expansion in FY26.

FBR Ltd reported a 57% revenue increase driven by property sales but posted a $29 million loss as it advances commercialization of its Hadrian X® robotic bricklayer and secures significant new funding.

Delorean Corporation reveals a strategic shift from EPC contractor to owner-operator of bioenergy assets, unveiling a $500 million-plus project portfolio despite a FY25 revenue dip and loss. The company is positioning itself at the forefront of Australia’s renewable gas market.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Synertec Corporation reported an 8% revenue decline in FY25 but achieved a 15% improvement in normalised EBITDA, driven by a strong second-half rebound in Engineering and a 90% surge in Powerhouse revenue.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Yojee Limited reported a 34% revenue decline to $675k and a 29% reduction in net loss to $6.02 million for FY2025, reflecting a strategic pivot and accelerated development of its MOSAIC freight forwarding platform. The company raised $8.9 million to fund growth and platform commercialization.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.